SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Randall, D. C.
Right arrow Articles by File, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randall, D. C.
Right arrow Articles by File, S. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Chronic Fatigue Syndrome
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome

Delia C. Randall

Psychopharmacology Research Unit, Centre for Neuroscience Research, King’s College London, London, UK and Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK

Fay H. Cafferty

MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK

John M. Shneerson

Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK, John.Shneerson{at}papworth.nhs.uk

Ian E. Smith

Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK

Meirion B. Llewelyn

General Medicine/Infectious Diseases, Royal Gwent Hospital, Newport, South Wales, UK

Sandra E. File

Psychopharmacology Research Unit, Centre for Neuroscience Research, King’s College London, London, UK

Fourteen patients (7 male, 7 female, 22-63 years), classified as having chronic fatigue syndrome (CFS), but without concurrent major depression, significant sleepiness or use of psychoactive medication, completed a double-blind, placebo-controlled, crossover study of the effects of the selective wakefulness-promoting agent, modafinil (200 and 400mg/day). The treatment periods were each 20 days, with washout periods of 2 weeks. The primary aim was to determine effects on cognition and the secondary aim was to determine effects on self-ratings of fatigue, quality of life and mood. Modafinil had mixed effects in two cognitive tasks. In a test of sustained attention, treatment with 200mg reduced the latency to correctly detect sequences, but 400mg increased the number of missed targets. In a test of spatial planning, the 200mg dose resulted in a slower initial thinking time for the easiest part of the task, whereas 400mg reduced the initial thinking time for the hardest part of the test. Lastly, in a test of mental flexibility and one of motor speed, patients performed worse whilst on modafinil (400mg), compared with the placebo period. No effects were observed on the performance of other psychometric tests or on self-ratings of fatigue, quality of life or mood, but this may have been due to insufficient statistical power. It is discussed whether the limited and mixed cognitive effects that we observed could have occurred by chance, or whether a subgroup of CFS patients with daytime sleepiness would have shown greater benefits.

Key Words: chronic fatigue syndrome • modafinil • cognitive performance • sleepiness • fatigue

Journal of Psychopharmacology, Vol. 19, No. 6, 647-660 (2005)
DOI: 10.1177/0269881105056531


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Adv. Psychiatr. Treat.Home page
B. Ng and A. O'Brien
Beyond ADHD and narcolepsy: psychostimulants in general psychiatry
Adv. Psychiatr. Treat., July 1, 2009; 15(4): 297 - 305.
[Abstract] [Full Text] [PDF]


Home page
Clin RehabilHome page
B. Van Houdenhove, L. Verheyen, K. Pardaens, P. Luyten, and P. Van Wambeke
Rehabilitation of decreased motor performance in patients with chronic fatigue syndrome: should we treat low effort capacity or reduced effort tolerance?
Clinical Rehabilitation, December 1, 2007; 21(12): 1121 - 1142.
[Abstract] [PDF]



Advertisement